𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Use of haplotype information to test involvement of the LRP gene in Alzheimer's disease in the French population

✍ Scribed by Verpillat, Patrice; Bouley, Sandrine; Campion, Dominique; Hannequin, Didier; Dubois, Bruno; Belliard, Serge; Puel, Michèle; Thomas-Antérion, Catherine; Agid, Yves; Brice, Alexis

Book ID
110025130
Publisher
Nature Publishing Group
Year
2001
Tongue
English
Weight
109 KB
Volume
9
Category
Article
ISSN
1018-4813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of the Brief Smell Identification Te
Use of the Brief Smell Identification Test for olfactory deficit in a Norwegian population with Alzheimer's disease
✍ Grete Kjelvik; Sigrid Botne Sando; Jan Aasly; Knut A. Engedal; Linda R. White 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

## Abstract ## Aims Several studies have shown that Alzheimer's disease (AD) is associated with hyposmia. Olfactory identification may be a cheap and simple additional test in the assessment of early cognitive changes. The sense of smell is influenced by factors such as experience and culture and

Use of cDNA microarray in the search for
Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia
✍ Giulio Maria Pasinetti 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

## Abstract Alzheimer's disease (AD) is the most common form of dementia, affecting as many as 4 million older persons and results from abnormal changes in the brain that most likely begin long before cognitive impairment and other clinical symptoms become apparent. Thus, efforts aimed at identifyi

The Use of Clinical Experience to Stage
The Use of Clinical Experience to Stage the Severity of Functional Impairments in Alzheimer's Disease
✍ SANFORD I. FINKEL; MANFRED BERGENER; FRANZ W. HULLA; MARK STEMMLER; JOHN E. OVER 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 906 KB

Experienced clinicians from Germany and the United States rated the stage of Alzheimer's disease at which each of 44 manifestations of cognitive, bebavioural, or functional impairment is considered most clinically relevant. The resulting data were subjected to three methods of metric scale analysis